A detailed history of Dimensional Fund Advisors LP transactions in Immunovant, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 573,447 shares of IMVT stock, worth $15.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
573,447
Previous 711,950 19.45%
Holding current value
$15.8 Million
Previous $30 Million 38.23%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$30.27 - $43.79 $4.19 Million - $6.07 Million
-138,503 Reduced 19.45%
573,447 $18.5 Million
Q4 2023

Feb 07, 2024

SELL
$31.31 - $44.19 $769,568 - $1.09 Million
-24,579 Reduced 3.34%
711,950 $30 Million
Q3 2023

Nov 09, 2023

SELL
$18.55 - $39.96 $2.49 Million - $5.36 Million
-134,168 Reduced 15.41%
736,529 $28.3 Million
Q2 2023

Aug 09, 2023

SELL
$14.2 - $23.75 $2.29 Million - $3.83 Million
-161,266 Reduced 15.63%
870,697 $16.5 Million
Q1 2023

May 12, 2023

SELL
$15.27 - $19.72 $4.06 Million - $5.24 Million
-265,645 Reduced 20.47%
1,031,963 $16 Million
Q4 2022

Feb 09, 2023

BUY
$6.59 - $17.75 $1.58 Million - $4.24 Million
239,149 Added 22.59%
1,297,608 $23 Million
Q3 2022

Nov 10, 2022

BUY
$3.93 - $6.37 $444,007 - $719,676
112,979 Added 11.95%
1,058,459 $5.91 Million
Q2 2022

Aug 12, 2022

BUY
$3.38 - $5.65 $860,260 - $1.44 Million
254,515 Added 36.83%
945,480 $3.69 Million
Q1 2022

May 13, 2022

BUY
$5.06 - $8.77 $2.09 Million - $3.62 Million
412,997 Added 148.58%
690,965 $3.81 Million
Q4 2021

Feb 09, 2022

BUY
$7.33 - $9.32 $1.94 Million - $2.46 Million
264,230 Added 1923.35%
277,968 $2.37 Million
Q3 2021

Nov 12, 2021

BUY
$7.01 - $11.37 $96,303 - $156,201
13,738 New
13,738 $119,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.